Carboplatin toxic effects on the peripheral nervous system of the rat

Annals of Oncology

Volumn 9, Issue 4, 1998, Pages 443-447

  Cavaletti, G ^a   Fabbrica, D ^a   Minoia, C ^b   Frattola, L ^a,c   Tredici, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Carboplatin; Neurophysiology; Neurotoxicity; Pathology; Rat

Indexed keywords

CARBOPLATIN; CISPLATIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON MICROSCOPY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MASS SPECTROMETRY; MICROSCOPY; MORPHOLOGY; MORPHOMETRICS; NERVE CONDUCTION; NEUROTOXICITY; NOCICEPTION; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; SATELLITE CELL; SPINAL GANGLION; TAIL FLICK TEST;

EID: 0031800167     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008231925889     Document Type: Article

References (17)

1. Boogerd W, ten Bokkel-Huinink WW, Dalesio O et al. Cisplatin induced neuropathy: Central, peripheral and autonomic nerve involvement. J Neuro Oncol 1990; 9: 255-63.
2. Cavaletti G, Tredici G, Marmiroli P et al. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 1992; 84: 364-71.
3. Daugaard GK, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cisplatin. Acta Neurol Scand 1987; 76: 86-93.
4. Gregg RW, Molepo JM, Monpetit VJA et al. Cisplatin neurotoxicity: The relationship between dosage, time and platinum concentration in tissues, and morphological evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
5. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: A study by light and electron microscopy and by morphometry. Acta Neuropathol (Berl) 1986; 69: 295-308.
6. Ruckdeshel JC. The future role of carboplatin. Semin Oncol 1994; 21 (Suppl 12): 114-8.
7. Bolis G. Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 1991; 22 (Suppl 14): 32-4.
8. Broun ER, Nichols CR, Mandanas R et al. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 1995; 16: 353-8.
9. Shea T, Graham M, Bernard S et al. A clinical and pharmaco-kinetic study of high-dose carboplatin. paclitaxel. granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or melastalic cancer. Semin Oncol 1995; 22 (Suppl 12): 80-5.
10. Tredici G, Cavaletti G, Petruccioli MG et al. Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neuro Toxicol 1994; 15: 701-4.
11. Cavaletti G, Minoia C, Schieppati M et al. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 1994; 29: 771-6.
12. Rose WC, Schurig JE. Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev 1985; 12 (Suppl A): 1-19.
13. Cornblath DR, Brown MJ. Influence of malnutrition on developing rat peripheral nerves. Exp Neurol 1988; 99: 403-11.
14. Cavaletti G, Tredici G, Pizzini G et al. Tissue platinum concentrations and cisplatin schedules. Lancet 1990; ii: 1003.
15. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989; 16: 195-211.
16. Hamers FPT, Gispen WH, Neijt JP. Neurotoxic side-effects of cisplatin. Eur J Cancer 1991; 27: 372-6.
17. 4 9 on neural transport in cisplatin induced neurotoxicity. Brain Res 1995; 676: 258-67.